Advertisement

Annals of Surgical Oncology

, Volume 17, Issue 2, pp 564–571 | Cite as

E2F1 Expression Predicts Outcome in Korean Women Who Undergo Surgery for Breast Carcinoma

  • Mi Jung Kwon
  • Eun Sook Nam
  • Seong Jin Cho
  • Hye Rim Park
  • Hyung Sik Shin
  • Jun Ho Park
  • Chan Heun Park
  • Won Jae Lee
Breast Oncology

Abstract

Background

The transcriptional factors E2F1 and E2F2 have been reported to be associated with improved chemosensitivity in various cancers. We aimed to investigate whether E2F1 and E2F2 can be used as predictors of chemosensitivity in hormone-receptor-negative breast cancers (HRNBCs), which are common in Korean women.

Methods

A total of 183 patients with primary breast cancer who had undergone surgical resection were evaluated on the basis of hormonal status, age, histological subtype and grade, tumor size, lymph node metastasis, and stage. The immunohistochemical expressions of E2F1 and E2F2 were analyzed for these histopathological data and patient survival.

Results

E2F1 expression was associated with low histological grade (grade 1) and larger tumor size (>2 cm), while E2F2 expression was correlated only with large tumor size (>2 cm). The E2F1-positive group had less tumor recurrences, lymph node metastases during follow-up, and distant metastases than the E2F1-negative group; E2F1 expression was found to be an independent predictive factor of more favorable survival among HRNBC patients on univariate and multivariate analyses, but E2F2 expression was not.

Conclusions

E2F1 may be a potential prognostic and predictive factor for clinical outcome and therapeutic results following adjuvant chemotherapy in HRNBC patients.

Keywords

Breast Cancer Adjuvant Chemotherapy Progesterone Receptor Invasive Lobular Carcinoma Hormone Receptor Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

The authors would like to thank Moon Sook Oh for her excellent technical assistance.

References

  1. 1.
    Lee JH, Yim SH, Won YJ, Jung KW, Son BH, Lee HD, et al. Population-based breast cancer statistics in Korea during 1993–2002: incidence, mortality, and survival. J Korean Med Sci. 2007;22:S11–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Argarwal G, Pradeep PV, Aggarwal V, Yip CH, Ceung P. Spectrum of breast cancer in Asian women. World J Surg. 2007;31:1031–40.CrossRefGoogle Scholar
  3. 3.
    Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete emission following combination chemotherapy for breast cancer. J Clin Oncol. 1996;14:2197–205.PubMedGoogle Scholar
  4. 4.
    Chopra R. The Indian scene. J Clin Oncol. 2001;19:(18)106–11.Google Scholar
  5. 5.
    Khan SA, Rogers MA, Khurana KK, Mequid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst. 1998;90:37–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Kushlinskii NE, Gershtein ES. Modern prospects for molecular-biochemical methods for evaluating biological “behavior” of breast neoplasms. Vestn Ros Akad Med Nauk. 2001;9:65–70.Google Scholar
  7. 7.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.CrossRefPubMedGoogle Scholar
  8. 8.
    Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–29.CrossRefPubMedGoogle Scholar
  9. 9.
    Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Stevens C, La Thangue NB. E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys. 2003;412:157–69.CrossRefPubMedGoogle Scholar
  11. 11.
    Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004;23:4709–16.CrossRefPubMedGoogle Scholar
  12. 12.
    La Thangue NB. The yin and yang of E2F1: balancing life and death. Nat Cell Biol. 2003;5:587–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee JY, Park CK, Park JO, Lim T, Park YS, Lim HY, et al. Impact of E2F1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res. 2008;14:82–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Belvedere O, Puglisi F, Di Loreto C, Cataldi P, Guglielmi A, Aschele C, et al. Lack of correlation between immunohistochemical expression of E2F1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann Oncol. 2004;15:55–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Han SH, Park KM, Bae BN, Kim KH, Kim HJ, Kim YD, et al. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat. 2003;82:11–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim EY, Jo HJ, Lee MJ. Expressions of E2F4 and E2F2 transcription factors in breast carcinoma. Korean J Pathol. 2005;39:301–6.Google Scholar
  17. 17.
    Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. Immunohistochemical expression of cyclin D1, E2F1, and Ki-67 in benign and malignant thyroid lesions. J Pathol. 2002;198:157–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is up-regulated in small cell lung carcinoma. Oncogene. 2001;20:1678–87.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, et al. E2F1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev. 2000;9:395–401.PubMedGoogle Scholar
  20. 20.
    Kim JY, Kim HW, Choi KU, Lee CH, Sol MY, Kang HJ, et al. Alteration of G1/S cell cycle regulatory proteins in ovarian epithelial tumors. Korean J Pathol. 2006;40:274–81.Google Scholar
  21. 21.
    Zacharators P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, Rezaei N, et al. Distinct expression patterns of the transcription factor E2F1 in relation to tumour growth parameters in common human carcinomas. J Pathol. 2004;203:744–53.CrossRefGoogle Scholar
  22. 22.
    Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst. 1999;91:874–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Ho GH, Calvano JE, Bisogna M, Van Zee KJ. Expression of E2F1 and E2F4 is reduced in primary and metastatic breast carcinomas. Breast Cancer Res Treat. 2001;69:115–22.CrossRefPubMedGoogle Scholar
  24. 24.
    Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER2- breast carcinomas. Cancer Res. 2007;67:6574–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Pruschy M, Wirbelauer C, Glanzmann C, Bodis S, Krek W. E2F1 has properties of a radiosensitizer and its regulation by cyclin A kinase is required for cell survival of fibrosarcoma cells lacking p53. Cell Growth Differ. 1999;10:141–6.PubMedGoogle Scholar
  26. 26.
    Elliott MJ, Farmer MR, Atienza C Jr, Stilwell A, Dong YB, Yang HL, et al. E2F1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumour Biol. 2002;23(2):76–86.CrossRefPubMedGoogle Scholar
  27. 27.
    Yamasaki L. Balancing proliferation and apoptosis in vivo: the goldilocks theory of E2F/DP action. Biochim Biophys Acta. 1999;1423:M9–15.PubMedGoogle Scholar
  28. 28.
    Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tumor atrophy in mice lacking E2F1. Cell. 1996;85:537–48.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Mi Jung Kwon
    • 1
  • Eun Sook Nam
    • 1
  • Seong Jin Cho
    • 1
  • Hye Rim Park
    • 3
  • Hyung Sik Shin
    • 1
  • Jun Ho Park
    • 2
  • Chan Heun Park
    • 2
  • Won Jae Lee
    • 4
  1. 1.Department of Pathology, Kangdong Sacred Heart HospitalHallym University Medical CollegeSeoulSouth Korea
  2. 2.Department of Surgery, Kangdong Sacred Heart HospitalHallym University Medical CollegeSeoulSouth Korea
  3. 3.Department of PathologyHallym Sacred Heart Hospital, Hallym University Medical CollegeAnyangSouth Korea
  4. 4.Department of Rehabilitation MedicineProvincial Gimcheon Silver HospitalGimcheonSouth Korea

Personalised recommendations